```html

Urticaria Pigmentosa Flare

What is Urticaria pigmentosa flare?

Urticaria pigmentosa (UP) is the most common form of cutaneous mastocytosis, a disorder in which an excess of mast cells accumulates in the skin. A “flare” refers to an acute worsening of the characteristic brown‑red macules or papules that become itchy, painful, or develop a hive‑like (urticarial) appearance after a trigger such as heat, friction, or certain medications. The flare can be localized to a single area or spread over large body surfaces and may be accompanied by systemic symptoms if large numbers of mast cells release histamine and other mediators into the bloodstream.

In children, UP often improves spontaneously by adolescence, whereas in adults it may persist or be a sign of systemic mastocytosis. Recognizing a flare early is important because the same mechanisms that cause skin changes can also provoke severe allergic‑type reactions.

Common Causes

Several environmental, pharmacologic, and physiological factors can provoke a urticaria pigmentosa flare:

• Physical stimuli – rubbing, pressure, friction (Koebner phenomenon), or sudden temperature changes.
• Heat and sweating – hot showers, saunas, exercise, or warm climates.
• Medications – opioids, non‑steroidal anti‑inflammatory drugs (NSAIDs), radiocontrast media, and certain antibiotics.
• Insect bites or stings – especially from bees, wasps, or mosquitoes.
• Alcohol – can trigger histamine release from mast cells.
• Emotional stress – cortisol fluctuations may increase mast‑cell degranulation.
• Infections – viral upper‑respiratory infections or bacterial skin infections.
• Hormonal changes – puberty, menstrual cycles, or pregnancy can modulate mast‑cell activity.
• Foods high in histamine – aged cheese, smoked fish, fermented products.
• Physical exercise – especially high‑intensity or prolonged workouts that cause heat and sweating.

Associated Symptoms

When a flare occurs, other signs often appear due to mast‑cell mediator release:

• Intense itching (pruritus) or burning sensation.
• Swelling (angio‑edema) of the lips, eyelids, or hands.
• Flushing or redness of the face and neck.
• Hives (wheals) that may be transient or persist for hours.
• Gastro‑intestinal upset – nausea, abdominal cramps, or diarrhea.
• Headache or dizziness.
• Palpitations or a rapid heart rate (tachycardia).
• Low‑grade fever or malaise.
• Rarely, systemic symptoms such as hypotension or anaphylaxis (see Emergency Warning Signs).

When to See a Doctor

Although many flares are mild and self‑limited, you should seek medical attention promptly if you notice:

• Rapid spreading of lesions covering large areas of the body.
• Swelling of the tongue, throat, or lips that makes swallowing or breathing difficult.
• Persistent wheezing, shortness of breath, or a feeling of “tightness” in the chest.
• Sudden drop in blood pressure (feeling faint, light‑headed, or collapsing).
• Severe abdominal pain or vomiting that does not improve.
• New onset of neurological symptoms such as confusion or seizures.
• Flares that last longer than 24‑48 hours or fail to improve with over‑the‑counter antihistamines.
• Any concern that the flare is a sign of systemic mastocytosis (persistent bone pain, unexplained bruising, or abnormal blood counts).

If you have a known diagnosis of mastocytosis, keep a written emergency plan and carry an epinephrine auto‑injector.

Diagnosis

Diagnosis combines a thorough history, physical examination, and selective laboratory or skin testing.

Clinical Evaluation

• History – duration of lesions, known triggers, family history of mast‑cell disorders, and any systemic symptoms.
• Physical exam – inspection of the skin for brown‑yellow macules, papules, or nodules that urticate when rubbed (Darier’s sign).

Skin Testing

• Darier’s sign – gentle rubbing of a lesion produces a wheal-and-flare reaction within minutes; a positive sign strongly supports mastocytosis.
• Biopsy – a 4‑mm punch biopsy stained with tryptase or CD117 (c‑Kit) confirms increased mast‑cell density.

Laboratory Tests (when systemic involvement is suspected)

• Serum tryptase level – elevated (>20 ng/mL) in many patients with systemic disease.
• Complete blood count with differential – looks for anemia, eosinophilia, or atypical cells.
• Liver function tests and alkaline phosphatase – to assess organ infiltration.
• Bone marrow aspirate/biopsy – indicated if serum tryptase is markedly high or if there are signs of hematologic disease.

Imaging (rarely required)

• Abdominal ultrasound or CT to rule out organomegaly when systemic mastocytosis is suspected.

Treatment Options

Treatment aims to control skin symptoms, prevent triggers, and, when needed, manage systemic disease.

Pharmacologic Therapies

• Second‑generation H1 antihistamines (cetirizine, loratadine, fexofenadine) – first‑line for itching and urtication; can be used daily.
• H2 antihistamines (ranitidine, famotidine) – added for gastrointestinal symptoms or refractory skin itching.
• Topical corticosteroids – low‑potency steroids (hydrocortisone 1%) for localized flares; avoid long‑term use on large areas.
• Systemic corticosteroids – short courses (e.g., prednisone 0.5 mg/kg for ≤7 days) for severe, widespread flares.
• Leukotriene receptor antagonists (montelukast) – useful adjunct for persistent itching.
• Mast‑cell stabilizers – cromolyn sodium oral suspension or topical form can reduce degranulation, though evidence is modest.
• Tyrosine‑kinase inhibitors – for systemic mastocytosis with KIT D816V mutation (e.g., midostaurin); prescribed by a hematologist.
• Epinephrine auto‑injector – prescribed for patients with a history of anaphylaxis or severe systemic reactions.

Home & Lifestyle Management

• Identify and avoid known triggers (keep a symptom diary).
• Wear loose, breathable clothing to reduce friction and heat.
• Take lukewarm showers; avoid hot baths and saunas.
• Apply cool compresses to itchy areas for 10‑15 minutes.
• Use fragrance‑free, hypoallergenic skin care products.
• Stay well‑hydrated; dehydration can worsen mast‑cell degranulation.
• Consider a low‑histamine diet if foods seem to trigger flares.

When Systemic Disease Is Present

Patients with systemic mastocytosis may require a multidisciplinary approach including hematology, dermatology, and allergy/immunology. Treatment may involve chemotherapy‑type agents, bone‑targeted therapy (e.g., bisphosphonates for osteoporosis), or investigational trials.

Prevention Tips

While it is impossible to eliminate all triggers, the following strategies can markedly reduce flare frequency:

1. Maintain a trigger log – note foods, activities, medications, and weather conditions that precede flares.
2. Temperature control – keep indoor environments cool (20‑22 °C) and avoid overheating during exercise.
3. Gentle skin care – avoid harsh scrubs, abrasive towels, and tight accessories that cause friction.
4. Medication review – discuss all prescribed and over‑the‑counter drugs with your physician; ask about alternatives to known mast‑cell activators.
5. Stress management – practice relaxation techniques (deep breathing, yoga, mindfulness) which can lower cortisol spikes.
6. Vaccination precautions – inform your immunizer about your condition; some vaccines may require a pre‑medication regimen of antihistamines.
7. Regular follow‑up – yearly dermatology or allergy visits help monitor disease progression and adjust therapy.
8. Carry emergency medication – keep an epinephrine auto‑injector and antihistamine tablets accessible at all times.

Emergency Warning Signs

Key Take‑aways

• Urticaria pigmentosa flare is an acute worsening of skin lesions caused by excess mast‑cell activation.
• Common triggers include heat, friction, certain medications, alcohol, and stress.
• Symptoms may be limited to the skin or involve systemic histamine effects.
• Prompt medical evaluation is essential for severe or rapidly progressing flares, especially when breathing or circulation is compromised.
• Diagnosis relies on clinical signs (Darier’s sign), skin biopsy, and—when indicated—serum tryptase and bone‑marrow studies.
• Treatment combines antihistamines, topical steroids, and, for severe cases, short courses of systemic steroids or targeted therapies.
• Preventive measures focus on trigger avoidance, temperature control, skin protection, and stress reduction.

References

1. Mayo Clinic. Urticaria pigmentosa. Updated 2023. https://www.mayoclinic.org
2. National Institutes of Health, National Library of Medicine. Cutaneous Mastocytosis. 2022. https://www.ncbi.nlm.nih.gov
3. Cleveland Clinic. Mastocytosis: Symptoms, Diagnosis, and Treatment. 2024. https://my.clevelandclinic.org
4. World Health Organization. Classification of Mast Cell Disorders. 2021. https://www.who.int
5. Hawryluk S, et al. “Management of Cutaneous Mastocytosis in Children and Adults.” J Allergy Clin Immunol Pract. 2023;11(5):1644‑1654.

```